



(86) Date de dépôt PCT/PCT Filing Date: 2014/09/29
(87) Date publication PCT/PCT Publication Date: 2015/04/02
(45) Date de délivrance/Issue Date: 2023/04/18
(85) Entrée phase nationale/National Entry: 2016/03/10
(86) N° demande PCT/PCT Application No.: EP 2014/070786
(87) N° publication PCT/PCT Publication No.: 2015/044418
(30) Priorité/Priority: 2013/09/30 (EP13186692.3)

(51) Cl.Int./Int.Cl. *C12M 3/06* (2006.01),
C07K 16/06 (2006.01), *C12N 5/00* (2006.01)
(72) Inventeurs/Inventors:
DE VILLIERS, ANN-MARIE, NL;
HENSGENS, CHARLES M. H., NL
(73) Propriétaire/Owner:
JANSSEN VACCINES & PREVENTION B.V., NL
(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : PROCEDE DE CLARIFICATION DE RECOLTE DE CULTURE DE CELLULES BRUTES A HAUTE DENSITE
(54) Title: METHOD FOR THE CLARIFICATION OF HIGH DENSITY CRUDE CELL CULTURE HARVEST

(57) Abrégé/Abstract:

The invention provides methods for the clarification of a cell broth with high cell density.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2015/044418 A1

(43) International Publication Date
2 April 2015 (02.04.2015)

(51) International Patent Classification:

C12M 3/06 (2006.01) *C07K 16/06* (2006.01)
C12N 5/00 (2006.01)

(21) International Application Number:

PCT/EP2014/070786

(22) International Filing Date:

29 September 2014 (29.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13186692.3 30 September 2013 (30.09.2013) EP

(71) Applicant: **CRUCELL HOLLAND B.V.** [NL/NL];
Archimedesweg 4, NL-2333 CN Leiden (NL).

(72) Inventors: **DE VILLIERS, Ann-Marie**; Archimedesweg
4-6, NL-2333 CN Leiden (NL). **HENSGENS, Charles,
M., H.**; Archimedesweg 4-6, NL-2333 CN Leiden (NL).

(74) Agents: **BESLIER, Victor** et al.; Archimedesweg 4-6,
NL-2333 CN Leiden (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))



WO 2015/044418 A1

(54) Title: METHOD FOR THE CLARIFICATION OF HIGH DENSITY CRUDE CELL CULTURE HARVEST

(57) Abstract: The invention provides methods for the clarification of a cell broth with high cell density.

Title: Method for the clarification of high density crude cell culture harvest

The invention relates to the field of cell culture purification. More particularly, it concerns improved methods for the clarification of a crude cell culture harvest with
5 high cell density.

Background of the invention

Recent developments in the field of the production of biological substances, such as biopharmaceuticals, vaccines and antibodies have created the need for large
10 scale manufacturing. Robust and high yield processes are needed to support the world with sufficient amounts of biological substances to combat all kinds of diseases.

For that reason, great efforts are being put into the optimization of cell based processes for the production of biological substances. In said processes, cells are being cultured at increasing densities in order to obtain higher product yields per
15 volume. Such high cell density processes are being disclosed in e.g. WO2004099396, WO2005095578 or WO2008006494.

WO2008006494 discloses processes for the culturing of cells that produce a biological substance in a bioreactor wherein the cell culture is circulated over a separation system. Said separation system separates the cells and the biological
20 substance from substances having a lower molecular weight than the biological substance. The cells and the biological substance are retained together in the reactor and are not separated from each other.

WO2005095578 discloses processes for the culturing of cells that produce a biological substance in a bioreactor wherein the cell culture is circulated over a filter
25 module, resulting in an outflow of liquid having a lower cell density than the cell culture and comprising the biological substance. The concentration of cells and biological substance in the outflow are substantially lower than in the bioreactor because the perfusion rate ranges between 1 and 13,7 L/day over a period of 23 days. (i.e. the processed volume is 20 times higher than the volume of the bioreactor).

30 Said optimized cell culture processes rely on the ability to culture cells at high cell density (e.g. higher than 10×10^6 cells/ml) with preservation of a high productivity per cell. Herewith, they offer a method to obtain a harvested solution with high concentration of proteins (e.g. antibodies) in a single bioreactor.

Processes wherein cells are cultured at high densities are prone to the accumulation of high amounts of cell debris and other impurities. These contaminants together with the cells have to be discarded further down the purification process, which is a cumbersome operation. As a first step solid material such as the cells and cell debris is to be separated from the cell broth fluid, a step called clarification. Examples of clarification methods used to-date include centrifugation, filtration (such as microfiltration, depth filtration and filtration through absolute pore size membranes) and expanded bed chromatography.

Many methods for purifying biological substances such as antibodies have been described earlier, e.g. in van Reis et al. (Biotechnology and bioengineering, 1991, Vol. 38, p. 413-422). Said reference describes a process comprising the steps of recovering cell culture fluid from fermenters and performing a cell-protein separation by tangential flow filtration. Said method was however only performed with low density cell cultures comprising about $0.5-4 \times 10^6$ cells/mL. It was not disclosed nor expected hitherto that such processes could be applied for a culture containing high cell densities. To the contrary, a strong suggestion could be inferred from the prior art that said process could not be applied on cultures containing high cell densities. In WO 2011/045381 for instance, which relates to the field of virus production, attempts have been made to directly clarify cell cultures having high cell density (see example 1 of WO 2011/045381). During said attempt, a proper clarification could not be achieved due to rapid clogging of the filter. Apparently, the high cell densities of the broth that was processed, impeded the purification step and rendered the tangential flow filtration (TFF) unsuitable for direct clarification. It was only after treatment of the high cell density broth with TritonTM (for lysing the cells) followed by domiphen bromide (DB) that the cell broth could be further processed (by clarification). The crude cell culture was not processed by TFF directly after harvest.

Based on these results, the skilled person would have been discouraged to treat a high cell density harvest directly (without pre-treatment) onto a clarification filter, expecting it to block rapidly.

Methods that are currently in use and considered state of the art for the treatment of high cell density cultures are for instance described in WO 2010/043700 or in Schirmer et al. (Bioprocess International, January 2010, p.32-39). The later reference relates to a process wherein the harvest is firstly diluted, subsequently

mixed with Si-PEI beads after which the beads settle and the supernatant is removed and filtered by depth filtration.

Drawbacks of this method are that the harvest is firstly diluted 3-5 times depending on the cell concentration in the harvest which implies that also the antibody
5 titers are diluted 3-5 times. Secondly, the chromatography resins used in large amounts during the process are very expensive and cannot be re-used. Finally, from our own experience with this technique, we have seen that the recovery is variable.

Since cell culture processes are being up-scaled and cells are being cultured at increasing densities, there is a need in the industry for downstream purification
10 processes that enable the treatment of high cell density suspensions, preferably at lower cost, high reliability and increased simplicity as compared to methods described by others. This applies in particular to the field of recombinant protein and antibody production.

15 **Summary of the invention**

We have found herein that crude cell culture harvests containing cells at high cell density as well as secreted proteins can be processed, without preliminary dilution, onto a TFF-device. Although said crude cell culture harvests are very concentrated and contain high loads of cell debris, they were successfully clarified
20 and no pressure build-up that led to blocking of the filter was observed.

In addition, the process according to the invention is faster and cheaper than processes used hitherto. Expensive chromatography resins and long lasting settling steps are no longer needed, and the process is easy to scale up.

The present invention therefore relates to methods for the clarification of a
25 crude cell culture harvest comprising cells as well as a secreted desired protein wherein the cells are at a cell density at harvest of at least 15×10^6 cells/ml and wherein at least 20% of said cells are viable, said method comprising the steps of:

- a. culturing cells in a bioreactor to a cell density of at least 15×10^6 cells/ml in order to obtain a crude cell culture harvest comprising desired secreted proteins,
- 30 b. subsequently processing substantially the complete crude cell culture harvest obtained in step a) by tangential flow filtration (TFF), where the processed volume of said crude cell culture harvest is less than two times the volume of the bioreactor in which the crude cell culture harvest has been produced, and wherein the desired protein is separated from the crude cell broth; and

c. recovering the desired protein in the filtrate.

In a preferred embodiment, the cell broth in step b) is subjected to TFF without preliminary dilution of the cell broth obtained in step a).

In some preferred embodiments said cells are at a cell density at harvest of at least 50×10^6 cell/ml. In other preferred embodiments said cells are at a cell density at harvest ranging between at least 50×10^6 cell/ml and 200×10^6 cell/ml.

In other preferred embodiments, the desired protein is a monoclonal antibody. In another preferred embodiment, the desired protein recovered in step b is further purified.

In other preferred embodiments the TFF is performed with a hollow fiber filter. Said hollow fiber filter preferably comprises a pore size ranging between 750 KDa and $0.65 \mu\text{m}$.

In other preferred embodiments the hollow fiber filter in the TFF device comprises a lumen diameter ranging between 0.25 mm and 1 mm.

Brief description of the figures

FIG. 1. Experimental set-up.

Detailed description of the invention

The present invention relates to methods for the clarification of a cell broth containing cells as well as a secreted protein comprising high cell density. In the context of the present invention “crude cell culture harvest”, “harvest” or “cell broth” means a cell culture inoculated with intact cells, and which may further contain culture medium as defined below, as well as secreted protein. Preferably the cells are protein-secreting cells.

“Clarification” means the separation of solid material such as the cells and cell debris from the cell broth fluid. According to the invention the secreted protein is present extracellularly and will thus be present in the cell broth fluid. In the present invention, “clarification” means the separation of the secreted protein from the cell-containing crude cell culture harvest.

In the process of the present invention, particularly when the cell density is extremely high, the starting material from the bioreactor is optionally diluted to a preferred cell density. However the processed volume of said crude cell culture harvest according to the invention does not exceed twice the volume of the bioreactor

in which the crude cell culture harvest has been produced. For the purpose of the present invention the so diluted material is still covered by the term crude cell culture harvest or cell broth. Preferably, the crude cell culture harvest or cell broth is subjected to TFF without preliminary dilution of the crude cell culture harvest.

5 Moreover, according to the present invention, it is substantially the complete crude cell culture harvest or cell broth obtained in step a) that is subsequently processed by TFF. "Substantially the complete crude cell culture harvest" means at least 70% of the entire crude cell culture harvest, preferably it means at least 80% of the entire crude cell culture harvest, more preferably at least 90% of the entire crude
10 cell culture harvest and even more preferably at least 95% of the entire crude cell culture harvest.

 With "secreted protein" is meant here protein which upon the production thereof by the cells are predominantly released (actively or passively) into the culture medium. With "desired" is meant here that the protein is intentionally being produced
15 making use of the cells.

 "About" as used in the present application means $\pm 10\%$, unless stated otherwise.

 The crude cell culture harvest or cell broth that is clarified according to the method of the invention may be obtained by any cell culturing method suitable for
20 attaining a cell density of the mammalian cells of at least 15×10^6 cells/mL. Suitable methods in this respect are described in e.g. WO2005095578, WO2004099396 and WO2008006494. According to the invention, the high cell density suspensions are obtained by culturing mammalian cells to high cell densities. Such culturing can be performed in (not limited) batch, fed-batch or perfusion mode.

25 In a preferred embodiment of the present invention, the cell density in said crude cell culture harvest is at least about 15×10^6 cells/mL, e.g. at least about 20×10^6 cells/mL, e.g. at least about 25×10^6 cells/mL, e.g. at least about 30×10^6 cells/mL, e.g. at least about 40×10^6 cells/mL, e.g. at least about 50×10^6 cells/mL.

 In another preferred embodiment of the present invention, the cell density in
30 said crude cell culture harvest is e.g. up to about 150×10^6 cells/mL, e.g. up to about 200×10^6 cells/mL, e.g. up to about 250×10^6 cells/mL, e.g. up to about 300×10^6 cells/mL.

According to the present invention, the clarified cell broth comprises cell densities ranging between 10×10^6 and 300×10^6 cells/mL, e.g. between about 15×10^6 and 250×10^6 cells/mL, e.g. between about 30×10^6 and 200×10^6 cells/mL, e.g. between about 50×10^6 and 150×10^6 cells/mL, e.g. between about 70×10^6 and 130×10^6 cells/mL, e.g. between about 90×10^6 and 110×10^6 cells/mL.

The cell density can be measured using a cell counter such as the Vi-CELL™ which uses the trypan blue exclusion method. Other suitable methods include cytometry, packed cell volume determination, or Coulter counters which uses the Electrical Sensing Zone Method.

Moreover, in the present invention, the viability of the cell culture prior to clarification remains higher than 20%. This means that at least 20% of the total amount of cells in the culture is viable at the start of the clarification process. In certain embodiments, the viability of the cell culture at the start of the clarification process is at least 40%, in further embodiments at least 60%, in further embodiments at least 80%, in further embodiments at least 90%. Viability can be measured using routine methods available to the skilled person, e.g. trypan blue exclusion, Casy cell count, and the like.

With "culture medium" is meant here the extracellular environment of the cells, which contains the nutrients and other constituents supporting the growth and production of cells, but may also contain waste products and/or host cell proteins (HCP) and/or material from lysed cells. The composition of the culture medium may vary in time during the course of the culturing of cells and at the stage of clarification may be depleted of one or more of the original constituents.

Once the proteins have been secreted in the cell culture, said proteins can be, according to the present invention, purified from the high cell density suspension or crude cell culture harvest. The first step of such a purification of desired proteins is clarification of the crude cell culture harvest.

Clarification

The crude cell culture harvest obtained from the previous culturing step is subsequently clarified to remove precipitated impurities and cell debris. According to the present invention said clarification is performed with a TFF device. Said TFF device preferably comprises a hollow fibre (see Fig. 1). Alternatively the TFF device comprises a cassette filter. During clarification, the secreted protein is separated from

the crude cell culture harvest with the tangential flow filtration device. The secreted protein is typically filtered tangentially through the filtration device and is recovered in the filtrate. Tangential flow filtration is a robust method of clarification of the present invention.

5 In general, all types of hollow fibre filters can be used for the present application. In a preferred embodiment the hollow fibres are the commonly used Discover, Explorer, Investigator and BioProducer filters from WaterSep. Other filters that are as well appropriate for the present method are the MidiKros, MiniKros, KrosFlo and CellFlo filters from Spectrum Labs. GE Healthcare also makes a very
10 wide range of hollow fibre filters in PS (polysulfone). Preferred materials for the hollow fiber filters are polyethersulfone (PES), polysulfone (PS), modified polyethersulfone (m-PES), mixed cellulose ester (ME) or ceramic filters.

According to the invention, the filters can have different pore sizes. According to the present invention, the hollow fibres comprise a pore size ranging between 250
15 kDa and 5 μm , e.g. between about 400 kDa and 4 μm , e.g. between about 500 kDa and 2.5 μm , e.g. between about 600 kDa and 1 μm . In a preferred embodiment the pore size is ranging between 750 kDa and 0.65 μm .

In another preferred embodiment the hollow fiber filter comprises a lumen diameter ranging between 0.1 and 6.0 mm, e.g. between 0.2 and 5 mm, e.g. between
20 0.2 and 3 mm, e.g. between 0.2 and 2 mm. In a preferred embodiment the lumen diameter is ranging between 0.25 and 1 mm. In an even more preferred embodiment the lumen diameter is about 0.5 mm.

The clarification method of the present invention removes at least 70%, more likely at least 80%, or even preferably at least 90% of the whole cells and cell debris
25 from the cell broth away from the suspension containing the desired proteins.

Following clarification of the crude cell culture harvest by tangential flow filtration, the desired proteins are recovered. With "recovery" is meant here obtaining the desired product essentially free from cells and cell debris. According to the present invention, the desired proteins are recovered in the filtrate of the TFF device.
30 Cell debris and other impurities remain in the retentate.

Methods of further purification

In order to further purify the suspension comprising the desired proteins obtained from the steps described above, the skilled person is aware of and can choose between

several purification steps. They comprise, e.g. filtration (such as depth filtration, microfiltration, ultrafiltration, diafiltration), chromatography (such as size exclusion chromatography, affinity chromatography, anion exchange chromatography, cation exchange chromatography, hydrophobic interaction chromatography, immobilized
5 metal affinity chromatography), aqueous two-phase extraction, precipitation or centrifugation. Shulka et al., 2007 and Kelly et al., 2009 provide an overview of further purification steps that are commonly used in the art, in particular for antibody purification.

In case of immunoglobulins as the desired proteins: affinity chromatography,
10 in particular protein A chromatography, and cation exchange chromatography are especially suitable separation methods.

In certain embodiments according to the invention, the clarified suspension containing the desired proteins can be treated by ultrafiltration. Ultrafiltration is used to concentrate the suspension containing the desired proteins. The suspension can be
15 concentrated 5 to 20 times.

In another embodiment of the present invention, a buffer exchange is performed via diafiltration. Diafiltration, or buffer exchange, using ultrafilters is a way for removal and exchange of salts, sugars and the like. The person skilled in the art knows under which conditions the buffer exchange should take place and which
20 buffers are appropriate for this step.

In another embodiment of the present invention, a following step can be an anion exchange chromatography step. During said step proteins are bound to a positively charged material, e.g. a membrane, cartridge or column. Subsequent elution allows for separating the proteins from impurities and remaining host cell DNA. In
25 yet another embodiment, the anion exchange chromatography step can be used as a flow through system.

In certain embodiments, it is preferred to use at least one anion exchange chromatography step. After the anion exchange chromatography step, the proteins may be sufficiently pure. In certain embodiments however a size exclusion
30 chromatography step is further performed to increase the robustness of the process. This step may be prior to or after the anion exchange chromatography step.

In any particular embodiment of the present invention, the anion exchange product can be diafiltered into formulation buffer and sterile filtered. Alternatively, an additional chromatography step (e.g. cation exchange) may be added either before or

after the diafiltration with the potential to improve the robustness of impurity and/or virus/prion clearance.

A sterile filtration step may be included in the process, which is helpful in eliminating bioburden. The product can be filtered through a 0.22 micron modified
5 polyvinylidene fluoride (PVDF) membrane (e.g. Millipore Millipak).

Scale of cell culture systems and down stream processing systems

The processes of the present invention are scalable. The cell cultures used in the present invention range from small scale cultures (e.g. 1-10 liter runs) to medium
10 scale cultures (e.g. 10-1000 L runs) up to large commercial scale preparations, such as 1000 to 10 000 L production runs. The tangential flow filtration step scale with culture volume while the optional and subsequent steps such as anion exchange chromatography scale with the input of desired proteins. Therefore, the size of the latter steps will be based on a bioreactor productivity estimate.

15 The purification of proteins from high density crude cell culture harvest which may contain high concentrations of proteins is made possible with the present invention. The possibility to process these cell suspensions, which contain high amounts of cell debris and host cell DNA allow for the purification of high quantities of proteins, such as antibodies per volume of suspension. It is the merit of this
20 invention to provide for a method for processing cell culture batches with high cell densities, containing high concentrations of desired proteins and therewith allowing for very high yields per processed volume. The present method, although it is applicable to large scale cell cultures will allow for cells to be cultured at smaller scale, yet to higher cell densities and still reach high product yields which can
25 efficiently be further processed. This method offers the possibility to process highly concentrated batches of desired proteins which will have a great impact on the entire biopharmaceutical purification industry.

Cells

30 Cells according to the present invention can be any type of cells, preferably mammalian cells such as CHO (Chinese Hamster Ovary) cells, hybridomas, BHK (Baby Hamster Kidney) cells, myeloma cells, human cells, for example HEK-293 cells, human lymphoblastoid cells, PER.C6 cells, mouse cells, for example NSO cells,

MDCK cells, Vero cells, amniocytes, duck cell lines, etc. In a preferred embodiment, the cells in the process of the present invention are protein-secreting cells.

In another preferred embodiment, the cells in the process of the present invention are PER.C6 cells or derivatives thereof (see U.S. Patent 5,994,128 and U.S. Patent 7,291,484). PER.C6 cells are exemplified by cells as deposited under ECACC
5 No. 96022940.

Secreted proteins

10 Secreted proteins, which may be produced by the cells according to the present invention (for example by expressing a recombinant gene coding therefore) are for example recombinant proteins, in particular receptors, enzymes, fusion proteins, blood proteins such as proteins from the blood coagulation cascade, multifunctional proteins such as for instance erythropoietin, virus or bacterial proteins for instance for use in
15 vaccines; immunoglobulins such as for example IgG or IgM, and the like. A secreted protein according to the present invention is more preferably an immunoglobulin or a part thereof and is produced by the cells. In a preferred embodiment the secreted desired protein is a monoclonal antibody. Preferably, the proteins produced by the cells can be used as an active ingredient in a pharmaceutical preparation.

20 The invention is further explained in the following examples. The examples do not limit the invention in any way. They merely serve to clarify the invention.

Examples

25 **Example 1:**

PER.C6 cells that express CR6261 antibody were cultured to a cell density of approximately 75×10^6 total cells/ml in a bioreactor at 37°C in serum-free culture medium according to the method disclosed in WO2008006494. The cell viability at harvest was about 68%.

30 2L of crude cell culture harvest were filtered by tangential flow filtration through the hollow fibre at a shear rate of 4000 s^{-1} until the inlet pressure began to rise sharply (corresponding to approximately 300×10^6 cells/ml in the retentate). The filter that was used in the TFF device was a $0.5 \mu\text{m}$ pore size hollow fiber filter from Spectrum Laboratories with 0.5 mm lumen diameter and 1050 cm^2 surface area
35 (cat#M1-M05E-360-F1N).

In a following step, diafiltration was started. The retentate was washed with 3 diafiltration volumes of 1x PBS and then concentrated further until filtration was no longer possible due to the high inlet pressure.

The final cell concentration in the retentate was approximately 570×10^6 total
5 cells/ml. The final permeate volume was 3064 g, the dilution factor was 1.6, and a product recovery of 81% was achieved. This shows that surprisingly the method of the present invention is appropriate for the direct clarification of a cell culture harvest comprising high densities of antibody-producing cells.

10 **Example 2:**

PER.C6 cells that express CR57 antibody were cultured to a cell density of approximately 82×10^6 total cells/ml in a bioreactor at 37°C in serum-free culture medium according to the method disclosed in WO2008006494. The cell viability at harvest was about 58%.

15 1L of crude cell culture harvest was filtered by tangential flow filtration through the hollow fibre at a shear rate of 4000 s^{-1} until the inlet pressure began to rise sharply (corresponding to approximately 270×10^6 cells/ml in the retentate). The filter that was used in the TFF device was a 0.5µm pore size hollow fiber filter from Spectrum Laboratories with 0.5 mm lumen diameter and 1050 cm^2 surface area
20 (cat#M1-M05E-360-F1N).

In a following step, diafiltration was started. The retentate was washed with 3 diafiltration volumes of 1x PBS and then concentrated further until filtration was no longer possible due to the high inlet pressure.

The final cell concentration in the retentate was approximately 540×10^6 total
25 cells/ml. The final permeate volume was 1755 g, so the dilution factor was 1.7, and a product recovery of 87% was achieved. This confirms that the method of the present invention is appropriate for the direct clarification of a cell culture harvest comprising high densities of antibody-producing cells.

30 **Example 3:**

PER.C6 cells that express CR8020 antibody were cultured to a cell density of approximately 194×10^6 total cells/ml in a bioreactor at 37°C in serum-free culture medium according to the method disclosed in WO2008006494. The cell viability at harvest was about 85%.

1L of crude cell culture harvest was filtered by tangential flow filtration through the hollow fibre at a shear rate of 4000 s^{-1} until the inlet pressure began to rise sharply (corresponding to approximately 300×10^6 cells/ml in the retentate). The filter that was used in the TFF device was a $0.5\mu\text{m}$ pore size hollow fiber filter from
5 Spectrum Laboratories with 0.5 mm lumen diameter and 1050 cm^2 surface area (cat#M1-M05E-360-F1N).

In a following step, diafiltration was started. The retentate was washed with 3 diafiltration volumes of 1x PBS and then concentrated further until filtration was no longer possible due to the high inlet pressure.

10 The final cell concentration in the retentate was approximately 610×10^6 total cells/ml. The final permeate volume was 1780 g, so the dilution factor was 1.8, and a product recovery of 97% was achieved. This shows that surprisingly, even at high cell densities around 200×10^6 total cells/ml, the method of the present invention is appropriate for the direct clarification of the cell culture harvest comprising antibody-
15 producing cells.

References

- Kamen and Henry, 2004. Development and optimization of an adenovirus production process. *J Gene Med* 2004; 6: S184–S192.
- Kelley et al. Process Scale Purification of Antibodies, Edited by Uwe Gottschalk
- 5 Copyright © 2009 John Wiley & Sons, Inc. Chapter 1: Downstream processing of monoclonal antibodies: current practices and future opportunities.
- Morenweiser et al. Downstream processing of viral vectors and vaccines. *Gene Therapy* (2005) 12, S103–S110.
- Schirmer B et al. Primary Clarification of Very High-Density Cell Culture
- 10 Harvests By Enhanced Cell Settling. *Bioprocess International*, January 2010, p.32-39.
- Shulka et al. Downstream processing of monoclonal antibodies - Application of platform approaches. *Journal of Chromatography B*, 848 (2007) 28–39.
- van Reis R, Leonard LC, Hsu CC, Builder SE. Industrial Scale Harvest of Proteins from Mammalian Cell Culture by Tangential Flow Filtration. *Biotechnology and bioengineering*, Vol. 38, p. 413-422 (1991).
- 15

Claims

1. A method for the clarification of a crude cell culture harvest comprising cells as well as a secreted desired protein wherein the cells are at a cell density at harvest of at least 15×10^6 cells/ml and up to 300×10^6 cells/mL, and wherein at least 20% of said cells are viable, said method comprising the steps of:
 - a. culturing cells in a bioreactor to a cell density of at least 15×10^6 cells/ml and up to 300×10^6 cells/mL in order to obtain a crude cell culture harvest comprising desired secreted proteins,
 - b. subsequently processing at least 70% of the crude cell culture harvest obtained in step a) by tangential flow filtration (TFF), where the processed volume of said crude cell culture harvest is less than two times the volume of the bioreactor in which the crude cell culture harvest has been produced, and where the desired protein is separated from the crude cell broth; and
 - c. recovering the desired protein in the filtrate.
2. The method according to claim 1, wherein the cells are at a cell density at harvest of at least 50×10^6 cell/ml.
3. The method according to claim 1, wherein the cells are at a cell density at harvest ranging between at least 50×10^6 cell/ml and 200×10^6 cell/ml.
4. The method according to any one of claims 1-3, wherein the desired protein is a monoclonal antibody.
5. The method according to any one of claims 1-3, wherein the desired protein recovered in step b is further purified.
6. The method according to any one of claims 1-4, wherein said TFF is performed with a hollow fiber filter.

1/1




FIG. 1